Targeting immune checkpoints in hematological malignancies

Targeting immune checkpoints in hematological malignancies

Abstract Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed treatment in solid tumor oncology. While immunotherapeutic approaches such as stem cell transplantation and anti-canc...

Full description

Bibliographic Details
Main Authors: Basit Salik, Mark J. Smyth, Kyohei Nakamura
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Journal of Hematology & Oncology
Subjects:
Immunotherapy
Immune checkpoint molecule
Tumor microenvironment
Hematological malignancy
Online Access:http://link.springer.com/article/10.1186/s13045-020-00947-6

Internet

http://link.springer.com/article/10.1186/s13045-020-00947-6

Similar Items